United States· US:61755-020_ad540294-d141-4655-a97b-abc9ae2795a3
Praluent
A alirocumab product containing alirocumab, registered in United States by Regeneron Pharmaceuticals, Inc.. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Alirocumab is registered in 15 of 19 countries.
Countries holding a registration under ATC C10AX14 (alirocumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Alirocumab · ATC C10AX14
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alirocumab costs, country by country.
Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alirocumab · price per daily dose (5.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$16.93
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ALIROCUMAB
- Manufacturer
- Regeneron Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- C10AX14
- ATC class
- Alirocumab
- Defined daily dose
- 5.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 19, 2026
Packs & prices · 6
- ndc1161755020011 SYRINGE, GLASS in 1 CARTON (61755-020-01) / 1 mL in 1 SYRINGE, GLASS
- ndc1161755020022 SYRINGE, GLASS in 1 CARTON (61755-020-02) / 1 mL in 1 SYRINGE, GLASS
- ndc1161755020041 SYRINGE, GLASS in 1 CARTON (61755-020-04) / 1 mL in 1 SYRINGE, GLASS
- ndc1161755-020-01
- ndc1161755-020-02
- ndc1161755-020-04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Alirocumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPRALUENTSanofi Winthrop Industrie, Gentilly
- SpainPRALUENT 150 MG SOLUCION INYECTABLE EN JERINGA PRECARGADASanofi Winthrop Industrie
- SwitzerlandPraluent 150 mg, solution injectable en stylo prérempliSanofi-Aventis (Suisse) SA
- IrelandPraluent 150 mg solution for injection in pre-filled penSanofi-Aventis Groupe
- FinlandPraluentSanofi Winthrop Industrie
- BelgiumPraluent 150 mgSanofi Winthrop Industrie
- IcelandPraluentSanofi Winthrop Industrie
- ItalyPRALUENT*1 penna preriempita SC 1 ml 150 mgSANOFI WINTHROP INDUSTRIE
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praluent
- Liechtenstein · Praluent
- Norway · Praluent
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4ddffe37-efec-4bc6-9f7b-d37960f27af6 GET /v1/drugs/4ddffe37-efec-4bc6-9f7b-d37960f27af6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "75",
"substance": "ALIROCUMAB",
"productndc": "61755-020",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125559",
"marketing_category": "BLA"
}See everything about alirocumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.